Uterine Cancer Trials

 

• STUDY17022
  
  First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors
  
  The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
  
  Study Information

  ---

  
  

• STUDY17262
  
  Combination of Autophagy Selective Therapeutics (COAST) in Relapsed Gynecological Cancers, Relapsed Prostate Cancer, or other Advanced Solid Tumors, a Phase I/II Trial
  
  Autophagy is a cancer cell survival mechanism that is involved in cancer growth, treatment resistance, and metastasis. Hydroxychloroquine and nelfinavir mesylate are agents that inhibit the process of autophagy. Metformin, dasatinib, and sirolimus stress autophagy.
  
  Study Information

  ---

  
  

• STUDY22462
  
  A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator’s Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy
  
  To compare the progression free survival (PFS) of olaparib plus temozolomide (Arm 1) as compared to investigator?s choice (trabectedin or pazopanib) (Arm 2) for the treatment of patients with advanced uLMS who have received two or more prior lines of therapy as determined by investigator (local site) assessment. To compare the overall survival (OS) of olaparib plus temozolomide (Arm 1) as compared to investigator?s choice (trabectedin or pazopanib) (Arm 2) for the treatment of patients with advanced uLMS who have received two or more prior lines of therapy.
  
  Study Information

  ---

  
  

• STUDY22631
  
  Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
  
  Among patients with metastatic extrapulmonary poorly differentiated small cell NEC, to compare overall survival (OS, measured from randomization) in a fixed sequence as follows: a. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus induction platinum/etoposide alone (Arm 3) b. Compare the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2) versus induction platinum/etoposide alone (Arm 3) c. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2)
  
  Study Information

  ---